Going into detail on what this term means and how it relates to health guidelines. This article may be incomplete.
The evolution of lipid lowering clinical trials for secondary prevention (those who've suffered a cardiovascular event) has not yet seen a floor to which lower LDL-C derived from lipid lowering therapies does not continue to demonstrate ongoing risk reduction. This also means that "residual risk" continues to be present in our highest risk patients. But the earlier we begin aggressive therapy and the longer we keep LDL-C at very low levels, the better they do.